糖调节受损和2型糖尿病患者血浆nesfatin-1水平的变化

采用酶联免疫法测定了初诊2型糖尿病患者、糖调节受损(IGR)患者、正常糖耐量(NGT)者血浆nesfatin-1水平.结果显示,2型糖尿病和IGR组血浆nesfatin-1水平明显高于NGT组[(1.91±0.79和1.80±0.80对1.41±0.58)μg/L,P＜0.01].血浆nesfatin-1水平与体重指数(BMI)、空腹血糖、空腹胰岛素、HbA1C、稳态模型评估的胰岛素抵抗指数(HOMA-IR)呈明显正相关(P＜0.05或P＜O.01).多元回归分析结果表明HOMA-IR和BMI分别是影响血浆nesfatin-1水平的独立相关因素(均P＜0.01).提示血浆nesfatin-1可能参与了胰岛素抵抗和2型糖尿病的发生和发展.

Changes of plasma nesfatin-1 levels in patients with impaired glucose regulation and type 2 diabetes mellitus

Plasma nesfatin-1 levels were assayed by ELISA in patients with impaired glucose regulation (IGR),type 2 diabetes mellitus( T2DM ),and healthy subjects with normal glucose tolerance( control group).The results showed that plasma nesfatin-1 levels in IGR and T2DM groups were significantly higher than that in control group [ ( 1.91 ±0.79 and 1.80±0.80 vs 1.41 ±0.58) μg/L,P＜0.01 ].Plasma nesfatin-1 levels were positively correlated with body mass index(BMI),HbA1c,waist hip ratio,fasting plasma glucose,fasting insulin,and homoestasis model assessment insulin resistant index( HOMA-IR,P＜0.05 or P＜0.01 ).Multiple regression analysis showed that BMI and HOMA-IR were independent related factors in influencing plasma nesfatin-1 levels (both P＜0.01 ).These results suggest that nesfatin-1 may partially contribute to the pathogenesis of insulin resistance and T2DM.